Abstract
The pre-treatment cell kinetics of 120 cervical tumours were assessed following the in vivo labelling with the thymidine analogue Bromodeoxyuridine (BrdUrd). In 89% both static and temporal kinetic parameters could be measured. Through the analysis of multiple biopsies from each tumour marked intra tumour heterogeneity was demonstrated. The median values for the most highly labelled sample analysed for each tumour were; S-phase duration (Ts) 12.1 h, BrdUrd labelling index (CLI) 9.5% and potential tumour doubling time 4.4 days. There was a significant elevation in CLI, but no difference in Ts, between tumour and non-neoplastic cervical tissue. There was a significant elevation in CLI, advanced stage and large size tumours. Although a significant elevation in CLI was found in aneuploid tumours this is likely to represent the systemic bias of the calculation methods, with no difference being seen between aneuploid and diploid tumours when BrdUrd labelling was measured with-out reference to the nuclei DNA content. The majority of these patients were treated with radiotherapy and cell kinetic data will be correlated with treatment response when adequate follow up has been achieved.
Highlights
Bromodeoxyuridine administration BrdUrd was obtained from the Department of Pharmacy at the University of Strathclyde
Multiple aneuploid populations were present in six cases, in ten the DNA/BrdUrd cytogram revealed elevated BrdUrd labelling associated with diploid and aneuploid cell populations present, which was interpreted as representing a tumour with a mixed ploidy population
If the diploid population originated from normal stroma or lymphocytes this degree of BrdUrd would not have been expected
Summary
Selection ofpatients Since April 1991 all patients with cervical carcinoma scheduled for either a staging procedure prior to radiotherapy or a radical hysterectomy have been asked to give written consent for the administration of BrdUrd; 138 patients have agreed. The participating hospitals are The Beatson Oncology Centre, Stobhill Hospital, and The Royal Infirmary, Glasgow. Ethical Committee approval was given for all hospitals. Bromodeoxyuridine administration BrdUrd was obtained from the Department of Pharmacy at the University of Strathclyde. BrdUrd 200 mg was dissolved in 100 ml of 0.9% saline and was administered intravenously over 15 min. The infusion was given 6-8 h prior to the predicted time of tumour sampling
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
